An aptamer-based, fluorescent and radionuclide dual-modality probe

Gui-Xiong Zhang1, Yan-Lan Liu2, Min Yang1

  • 1Department of Nuclear Medicine, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, China.

Biochimie
|February 22, 2020
PubMed

Insights

Researchers developed a novel dual-modality aptamer probe for cancer imaging. This probe combines fluorescent and radionuclide properties, showing specific binding to hepatoma cells for potential theranostics.

Area of Science:

  • Biotechnology
  • Molecular Imaging
  • Nucleic Acid Chemistry

Background:

  • Aptamers are effective molecular probes for targeted delivery of imaging or therapeutic agents.
  • Developing dual-modality probes enhances diagnostic capabilities and theranostic potential.

Purpose of the Study:

  • To create a novel dual-modality (fluorescent and radionuclide) probe using a truncated aptamer.
  • To evaluate the in vitro stability and binding affinity of the developed probe.

Main Methods:

  • Truncation of aptamer JHIT2 to create JHIT2e using RNAstructure and mfold software.
  • Conjugation of carboxyfluorescein (FAM) and Iodine-131 to the truncated aptamer JHIT2e.
  • In vitro cell uptake and fluorescence imaging assays using HepG2 cells.

Main Results:

  • The truncated aptamer JHIT2e retained specificity and affinity for HepG2 cells.
  • The dual-modality probe 131I-FAM-JHIT2e exhibited both fluorescence and radioactivity signals.
  • The probe demonstrated specific binding to the human hepatoma cell line HepG2 in vitro.

Conclusions:

  • A novel aptamer-based dual-modality probe (131I-FAM-JHIT2e) was successfully developed.
  • The probe maintains specific binding to HepG2 cells, suitable for dual-modality imaging.
  • This work provides a foundation for aptamer-based theranostic agents.